SCNI
Price
$1.54
Change
+$0.01 (+0.65%)
Updated
Aug 20, 04:59 PM (EDT)
Capitalization
1.53M
SYRE
Price
$16.34
Change
+$0.23 (+1.43%)
Updated
Aug 20, 04:59 PM (EDT)
Capitalization
973.06M
78 days until earnings call
Interact to see
Advertisement

SCNI vs SYRE

Header iconSCNI vs SYRE Comparison
Open Charts SCNI vs SYREBanner chart's image
Scinai Immunotherapeutics
Price$1.54
Change+$0.01 (+0.65%)
Volume$400
Capitalization1.53M
Spyre Therapeutics
Price$16.34
Change+$0.23 (+1.43%)
Volume$21.73K
Capitalization973.06M
SCNI vs SYRE Comparison Chart in %
Loading...
SCNI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCNI vs. SYRE commentary
Aug 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCNI is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 21, 2025
Stock price -- (SCNI: $1.53 vs. SYRE: $16.11)
Brand notoriety: SCNI and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCNI: 9% vs. SYRE: 90%
Market capitalization -- SCNI: $1.53M vs. SYRE: $973.06M
SCNI [@Biotechnology] is valued at $1.53M. SYRE’s [@Biotechnology] market capitalization is $973.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.19B to $0. The average market capitalization across the [@Biotechnology] industry is $1.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCNI’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • SCNI’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SCNI is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCNI’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • SCNI’s TA Score: 5 bullish, 3 bearish.
  • SYRE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SCNI is a better buy in the short-term than SYRE.

Price Growth

SCNI (@Biotechnology) experienced а +6.99% price change this week, while SYRE (@Biotechnology) price change was +1.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.03%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +22.21%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (-0.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($973M) has a higher market cap than SCNI($1.53M). SYRE has higher P/E ratio than SCNI: SYRE (1.72) vs SCNI (1.19). SYRE YTD gains are higher at: -30.799 vs. SCNI (-54.260). SCNI has higher annual earnings (EBITDA): 7.8M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. SCNI (1.03M). SYRE has less debt than SCNI: SYRE (0) vs SCNI (1.23M). SCNI has higher revenues than SYRE: SCNI (452K) vs SYRE (0).
SCNISYRESCNI / SYRE
Capitalization1.53M973M0%
EBITDA7.8M-222.15M-4%
Gain YTD-54.260-30.799176%
P/E Ratio1.191.7269%
Revenue452K0-
Total Cash1.03M527M0%
Total Debt1.23M0-
FUNDAMENTALS RATINGS
SCNI vs SYRE: Fundamental Ratings
SCNI
SYRE
OUTLOOK RATING
1..100
167
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9561
P/E GROWTH RATING
1..100
7482
SEASONALITY SCORE
1..100
2550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCNI's Valuation (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for SYRE (73). This means that SCNI’s stock grew somewhat faster than SYRE’s over the last 12 months.

SCNI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that SCNI’s stock grew similarly to SYRE’s over the last 12 months.

SCNI's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that SCNI’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (61) in the Pharmaceuticals Major industry is somewhat better than the same rating for SCNI (95). This means that SYRE’s stock grew somewhat faster than SCNI’s over the last 12 months.

SCNI's P/E Growth Rating (74) in the Pharmaceuticals Major industry is in the same range as SYRE (82). This means that SCNI’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCNISYRE
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 8 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 7 days ago
88%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
SCNI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEMRX12.74N/A
N/A
American Century Emerging Markets R
PFGKX38.75N/A
N/A
Victory Pioneer Fundamental Growth R6
EMSLX19.88N/A
N/A
Shelton Emerging Markets Investor
TSMVX28.83N/A
N/A
Transamerica Small/Mid Cap Value I2
BLYPX34.30-0.36
-1.04%
American Beacon Man Lg Cp Growth Inv

SCNI and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCNI has been closely correlated with TAOX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if SCNI jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCNI
1D Price
Change %
SCNI100%
-3.77%
TAOX - SCNI
73%
Closely correlated
-16.55%
SYRE - SCNI
43%
Loosely correlated
-4.90%
MBIO - SCNI
37%
Loosely correlated
-2.96%
BIVI - SCNI
34%
Loosely correlated
-9.14%
VANI - SCNI
32%
Poorly correlated
-2.42%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-4.90%
CGON - SYRE
61%
Loosely correlated
-2.18%
IDYA - SYRE
60%
Loosely correlated
-2.83%
BEAM - SYRE
58%
Loosely correlated
-4.39%
XNCR - SYRE
57%
Loosely correlated
-2.82%
CRNX - SYRE
55%
Loosely correlated
-1.04%
More